OnabotulinumtoxinA in the Treatment of Patients with Chronic Migraine: Clinical Evidence and Experience

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2017 Dec 6

PMID 29204191

Citations 3

Authors

Chia-Chun Chiang

Amaal J Starling

Affiliations

Soon will be listed here.

Abstract

Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4-2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 2010 for the treatment of chronic migraine. The approval was made based on results from two large, randomized, double-blind placebo-controlled trials: the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. Since then, numerous studies have been performed investigating the short-term and long-term benefits, risks and complications of the use of onabotulinumtoxinA injections for the treatment of chronic migraine. The purpose of this narrative review is to describe the currently available clinical evidence for the use of onabotulinumtoxinA injections for treating patients with chronic migraine.

Citing Articles

Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic.

Santana L, Liu C J Pediatr Pharmacol Ther. 2021; 26(2):151-156.

PMID: 33603578 PMC: 7887883. DOI: 10.5863/1551-6776-26.2.151.

Manual therapy for chronic migraine: a pragmatic randomised controlled trial study protocol.

Odell J, Clark C, Hunnisett A, Ahmed O, Branney J Chiropr Man Therap. 2019; 27:11.

PMID: 30962877 PMC: 6436233. DOI: 10.1186/s12998-019-0232-4.

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.

Vikelis M, Argyriou A, Dermitzakis E, Spingos K, Makris N, Kararizou E J Headache Pain. 2018; 19(1):87.

PMID: 30225735 PMC: 6755578. DOI: 10.1186/s10194-018-0918-3.

References

Evers S, Afra J, Frese A, Goadsby P, Linde M, May A . EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009; 16(9):968-81. DOI: 10.1111/j.1468-1331.2009.02748.x. View

Moon H, Seo J, Park S . Perceived stress in patients with migraine: a case-control study. J Headache Pain. 2017; 18(1):73. PMC: 5520838. DOI: 10.1186/s10194-017-0780-8. View

Hepp Z, Rosen N, Gillard P, Varon S, Mathew N, Dodick D . Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database. Cephalalgia. 2015; 36(9):862-74. DOI: 10.1177/0333102415621294. View

Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R . OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30(7):793-803. DOI: 10.1177/0333102410364676. View

Bigal M, Serrano D, Reed M, Lipton R . Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71(8):559-66. DOI: 10.1212/01.wnl.0000323925.29520.e7. View

Khalil M, Zafar H, Quarshie V, Ahmed F . Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014; 15:54. PMC: 4166400. DOI: 10.1186/1129-2377-15-54. View

Bratbak D, Nordgard S, Stovner L, Linde M, Dodick D, Aschehoug I . Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2016; 37(4):356-364. PMC: 5394468. DOI: 10.1177/0333102416648328. View

Diener H, Bussone G, van Oene J, Lahaye M, Schwalen S, Goadsby P . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7):814-23. DOI: 10.1111/j.1468-2982.2007.01326.x. View

Rizzoli P . Acute and preventive treatment of migraine. Continuum (Minneap Minn). 2012; 18(4):764-82. DOI: 10.1212/01.CON.0000418641.45522.3b. View

10.

Pedraza M, de la Cruz C, Ruiz M, Lopez-Mesonero L, Martinez E, de Lera M . OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus. 2015; 4:176. PMC: 4398682. DOI: 10.1186/s40064-015-0957-z. View

11.

Silberstein S, Blumenfeld A, Cady R, Turner I, Lipton R, Diener H . OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013; 331(1-2):48-56. DOI: 10.1016/j.jns.2013.05.003. View

12.

Magalhaes E, Menezes C, Cardeal M, Melo A . Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010; 112(6):463-6. DOI: 10.1016/j.clineuro.2010.02.004. View

13.

Rothrock J, Bloudek L, Houle T, Andress-Rothrock D, Varon S . Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache. 2014; 54(10):1565-73. PMC: 4282490. DOI: 10.1111/head.12456. View

14.

Russo A, Silvestro M, Tessitore A, Tedeschi G . The "Ram's Horns Sign": A Case Report of an Unusual Side Effect of OnabotulinumtoxinA in a Chronic Migraine Patient. Headache. 2016; 56(10):1656-1658. DOI: 10.1111/head.12883. View

15.

Simpson D, Hallett M, Ashman E, Comella C, Green M, Gronseth G . Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19):1818-26. PMC: 4862245. DOI: 10.1212/WNL.0000000000002560. View

16.

Negro A, Curto M, Lionetto L, Martelletti P . A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2016; 17:1. PMC: 4720620. DOI: 10.1186/s10194-016-0591-3. View

17.

Blumenfeld A, Aurora S, Laranjo K, Papapetropoulos S . Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015; 15:100. PMC: 4489131. DOI: 10.1186/s12883-015-0353-x. View

18.

Aurora S, Winner P, Freeman M, Spierings E, Heiring J, DeGryse R . OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011; 51(9):1358-73. DOI: 10.1111/j.1526-4610.2011.01990.x. View

19.

Starling A, Dodick D . Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin Proc. 2015; 90(3):408-14. DOI: 10.1016/j.mayocp.2015.01.010. View

20.

Ahmed F, Zafar H, Buture A, Khalil M . Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus. 2015; 4:589. PMC: 4628076. DOI: 10.1186/s40064-015-1386-8. View